Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06558188 · ClinicalTrials.gov registry record · Phase 4
Combined Anabolic Therapy
A Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06558188 is a Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06558188, a Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Conditions Studied
Interventions
- DRUG Romosozumab
- DRUG Teriparatide
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06558188
The ClinicalTrials.gov registry entry for NCT06558188 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Romosozumab is the first listed.
NCT06558188 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06558188 about?
NCT06558188 is a clinical study titled "Combined Anabolic Therapy". In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
What is the current status of trial NCT06558188?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-02-03. Estimated completion is 2027-07-01.
What conditions does trial NCT06558188 study?
This clinical trial studies the following conditions: Osteoporosis, Osteoporosis, Postmenopausal.
What interventions are being tested in trial NCT06558188?
The interventions under investigation include: Romosozumab (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT06558188?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06558188 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Muscle Impact of Treating Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.